MXPA00012300A - Dietary supplement derived from fermented milks for the prevention of osteoporosis - Google Patents
Dietary supplement derived from fermented milks for the prevention of osteoporosisInfo
- Publication number
- MXPA00012300A MXPA00012300A MXPA/A/2000/012300A MXPA00012300A MXPA00012300A MX PA00012300 A MXPA00012300 A MX PA00012300A MX PA00012300 A MXPA00012300 A MX PA00012300A MX PA00012300 A MXPA00012300 A MX PA00012300A
- Authority
- MX
- Mexico
- Prior art keywords
- weight
- granules
- lactobacill
- mixture
- milk
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 25
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 12
- 230000002265 prevention Effects 0.000 title claims description 7
- 235000015140 cultured milk Nutrition 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 239000000126 substance Substances 0.000 claims abstract description 26
- 239000011575 calcium Substances 0.000 claims abstract description 20
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 20
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 15
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000011777 magnesium Substances 0.000 claims abstract description 15
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 15
- 239000011707 mineral Substances 0.000 claims abstract description 15
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- 238000000855 fermentation Methods 0.000 claims abstract description 10
- 230000004151 fermentation Effects 0.000 claims abstract description 10
- 150000004676 glycans Polymers 0.000 claims abstract description 9
- 239000005017 polysaccharide Substances 0.000 claims abstract description 9
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 9
- 150000004804 polysaccharides Polymers 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 235000020200 pasteurised milk Nutrition 0.000 claims abstract description 6
- 239000011159 matrix material Substances 0.000 claims abstract description 5
- 230000003412 degenerative Effects 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract 2
- 235000013305 food Nutrition 0.000 claims abstract 2
- 238000000926 separation method Methods 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims description 24
- 235000015141 kefir Nutrition 0.000 claims description 16
- 241000235070 Saccharomyces Species 0.000 claims description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 10
- 239000011591 potassium Substances 0.000 claims description 10
- 229910052700 potassium Inorganic materials 0.000 claims description 10
- 238000007792 addition Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 210000004080 Milk Anatomy 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 240000009163 Acetobacter aceti Species 0.000 claims description 4
- 235000007847 Acetobacter aceti Nutrition 0.000 claims description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 3
- 241000192132 Leuconostoc Species 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 244000253911 Saccharomyces fragilis Species 0.000 claims 2
- 235000018368 Saccharomyces fragilis Nutrition 0.000 claims 2
- 244000057717 Streptococcus lactis Species 0.000 claims 2
- 235000014897 Streptococcus lactis Nutrition 0.000 claims 2
- 235000020247 cow milk Nutrition 0.000 claims 2
- 235000020254 sheep milk Nutrition 0.000 claims 2
- 206010006956 Calcium deficiency Diseases 0.000 claims 1
- 240000001929 Lactobacillus brevis Species 0.000 claims 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims 1
- 241000108055 Lactobacillus kefiranofaciens Species 0.000 claims 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims 1
- 101700062671 SIAE Proteins 0.000 claims 1
- 230000001464 adherent Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000020251 goat milk Nutrition 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 description 13
- 235000015097 nutrients Nutrition 0.000 description 13
- 241000186660 Lactobacillus Species 0.000 description 10
- 229940039696 Lactobacillus Drugs 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 210000000988 Bone and Bones Anatomy 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 229940029983 VITAMINS Drugs 0.000 description 5
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001502 supplementation Effects 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229930003231 vitamins Natural products 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000036912 Bioavailability Effects 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000035514 bioavailability Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000002346 musculoskeletal system Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940069978 CALCIUM SUPPLEMENTS Drugs 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 201000010538 lactose intolerance Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003449 preventive Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2S)-2-amino-3-methylbutanoic acid;(2S)-2-amino-4-methylpentanoic acid;(2S,3S)-2-amino-3-methylpentanoic acid Chemical class CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 208000009576 Hypercholesterolemia Diseases 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940029985 MINERAL SUPPLEMENTS Drugs 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 229940053207 Niacin Drugs 0.000 description 1
- 229940116542 OTHER NUTRIENTS in ATC Drugs 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 229960002477 Riboflavin Drugs 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 210000000587 Skeletal Muscle Fibers Anatomy 0.000 description 1
- 210000002356 Skeleton Anatomy 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 206010040836 Skin dystrophy Diseases 0.000 description 1
- 206010040837 Skin dystrophy Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000000513 bioprotective Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960004729 colecalciferol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 230000004092 musculoskeletal function Effects 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000529 probiotic Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 229960002862 pyridoxine Drugs 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin D3 Drugs 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
A process is described for manufacturing dietary supplements (food integrators) by means of a natural fermentation, including the following steps:a) preparation of a"mix"at a 18°Centigrade temperature, containing one or more types of pasteurized milk from animal origin;b) introduction in such a"basic material"of a 1.5-4.5%in weight of polysaccharide"grains"mainly formed"friendly bacteria";c) maintenance of the previous substance at a 18-25°Centigrade temperature for a first period of 6-12 hours then adding a quantity of 1-3%in weight of a second pool of polysaccharide"grains", mainly formed by yeasts;d) maintenance of the substance at 18-25°C during a second period of 6-12 hours, by adding again 2.5.-6.5%in weight of"grains"mainly formed by yeasts, then adding some minerals (calcium, magnesium, etc.) in proportion 0.2-1.2%of weight;e) separation, by filtration, of different components of the substance, among whose a"residual matrix"composed by grains of polysaccharides containing bacteria and yeasts;f) drying of the substance, after filtration, for obtaining a fine powder;g) preparation of various dietary supplements, presented in tablets or"sachets"or other formulations, useful in the treatment of osteoporosis and other degenerative conditions.
Description
DIETETIC SUPPLEMENT DERIVED FROM FERMENTED MILKS FOR THE PREVENTION OF THE
OSTEOPOROSIS
Description of the Invention The present invention relates to products that are used as dietary supplements or nutritional supplements for the supplementation of nutrition and diet by taking substances, mainly of natural origin, which provide the necessary elements for nutrition and in this way for the proper maintenance of the essential functions of the body (such as the formation and preservation of bones, muscles, skin, related tissues and the like). More particularly, the present invention relates to a process for obtaining a natural dietary supplement that has proven to be very effective for the prevention and treatment of osteoporosis and other diseases primarily due to deficiencies of calcium, magnesium and potassium in the body. In the current state of our technical and scientific knowledge, it is well known that an adequate supply of a variety of nutritional substances,
Ref: 125315
commonly called ^ nutrients "(such as minerals, vitamins, proteins, and others) are of fundamental importance for the proper development of bodily tissues and for the vital functions of the body, and that the deficiencies or imbalances of these nutrients are normally concomitant with the current pathological conditions (particularly those of a 'degenerative' and / or chronic type that can affect various parts of the body, for example the skeleton and the blood vessels, etc.) It is also known that the main nutrients are ingested with the diet, and therefore that, if the latter are sufficiently appropriate and balanced, and if the body is in a normal operating state in terms of assimilation and conversion of these nutrients, there should be no problems with respect to maintaining the conditions of good health from this point of view.In fact, it often happens that the diet of an individual, and in cluso, in fact, especially in industrialized countries, presents imbalances due to deficiencies and / or excesses that over a period of time can cause serious damage to health. Many diseases, which are then treated. with different
drugs, are also due to unbalanced nutritional intake and it is well known that these can be prevented and even cured by restoring lost balance. It is also known, moreover, that the various products that commonly come under the definition of dietary supplements have been produced and used to solve the aforementioned problems and that, therefore, they are a familiar aspect of the current state of the art. These supplements consist of combinations of various substances (nutrients) that are obtained through the processes of chemical synthesis or extraction of various materials (vitamins, minerals of vegetable or animal origin) that are formed into compounds in a particular formula and are presented in the form of tablets or capsules, or other types of preparations that can be taken orally. The administration of these preparations presents a complete range of drawbacks, the most important of which are: (1) the origin of the nutrients that are used (obtained by synthesis or extraction), which are normally unsuitable for the human body; (2) difficulties of assimilation due to the source and the materials that are used, which limit
substantially the bioavailability of the substances that are administered; (3) the respective proportions of the various nutrients that are present in the product that is administered, which are commonly predetermined independently from each other, without due consideration of the balance that is in fact found in nature and in the processes metabolic, and that constitute one of the key factors for the aforementioned balanced diet that is required for the effective conditions of health and well-being of the body. As a consequence of the considerations described in this, the inventor of the present invention concludes that the solutions to the aforementioned problems that are effectively useful for the health and balance of the body should be sought in processes of completely natural preparation, by 'directing' exclusively the chemical transformations carried out biologically by microorganisms such as, for example, lactobacteria and yeasts, in order to influence them in the way they are required, the condition of a good development and maintenance of the health of the musculoskeletal system and in
The particularity of bones is recognized as a fundamental health problem, and widely widespread. It is related to both the problems of diet and the use of certain drugs, as well as the manifestation of degenerative processes as a result of aging that can lead to the onset of osteoporosis (which consists of a reduced density and elasticity of the bones with an increase consequent in its fragility) and collateral conditions of an inflammatory and painful type that even lead to a final risk of sudden fractures (in this case they are not due to any obvious serious trauma). The subjects that are most 'at risk' are women, particularly during the post-menopausal period, and those individuals with a particular 'genetic risk' whose specific analyzes have identified them as being present in 15% or more of the population general. A variety of effective drugs against this disease is currently available, but now it has been established that the best method for both prevention and therapy of osteoporosis must necessarily involve adequate dietary supplementation based on minerals such as
calcium and magnesium with the possible addition of vitamin D3. However, this 'supplementation' is in most cases implemented by administering poorly assimilable products and an unsatisfactory biological quality containing inorganic calcium or calcium which, in any case, is not absorbed in the intestines due to a number of factors They block its absorption to a substantial degree.As an alternative to this supplementation, diets rich in dairy products and cheese are usually recommended, they provide a good supply of calcium (and also magnesium), but unfortunately have several problems that normally they are underestimated, such as: (a) problems of poor digestion or even lactose intolerance, (b) excessively high cholesterol levels, (c) unwanted intake of calories and fats, the inventor of the present invention therefore seeks a solution that can provide a product that has better ability to overcome the problems previously e mentioned, in the form of a supplement that is demonstrably effective, reliable and economical, that is, by developing a product that: (1) guarantees
the supply of adequate amounts of calcium, magnesium and other nutrients that are useful for bone and metabolism for the purposes of musculoskeletal functions; (2) ensure an assimilation of the various nutrients; (3) ensure digestion capacity and avoid intolerance; and (4) has the characteristics of a fully biocompatible biological substance. For this purpose, the inventor has discovered a process that is the subject of the present invention, which is outlined in the preamble of claim 1 and of which its inventive characteristics are described in the characterizing part of this claim. The present invention also relates to dietary supplements that can be obtained by this process and its use for the prevention and therapy of osteoporosis and other diseases due substantially to deficiencies of calcium, magnesium and potassium. The process according to the invention makes it possible to obtain a 'nutrient complex', by means of whose definition a nutritional substance of natural origin is implied, which is the result of a biological processing by microorganisms (the so-called
"beneficial microorganisms", such as lactobacilli, etc.), which contain all the desired nutrients, and particularly calcium, magnesium and potassium, with the desired characteristics of good assimilation, tolerance and efficacy.The inventor begins to select the products that can obtained from various types of fermented milk, which are products that differ so much from the type of milk (from cow, sheep, goat, mare) and the type of microorganisms that are used, as well as the methods by which the fermentation process is carried out. A particular type of fermentation product is identified in this way, which is comparable to a substance that is traditionally known in the countries of the Middle East and Eastern Europe under the name of Kefir, which is endowed with optimal characteristics in the manner of a "nutritional complex." Kefir is a type of yogurt, which can be obtained through the fermentation of milk through the dual action of a variety of lactobacilli and yeasts, of which the appropriate combination makes it possible to obtain a product biologically processed with the required characteristics The addition, during the fermentation process, of the desired substances
(for example, although not exclusively, calcium) allows the 'enrichment' of the nutrient complex so that it can be used specifically for a certain type of application (for example, for the treatment of osteoporosis). or more of the minerals, fixing them in their cells and ensuring their bioavailability.To achieve the desired objectives, the inventor, after meticulously studying the natural and traditional processes implemented in the areas mentioned above, concludes that natural food supplements with a highly effective action can be obtained through the work of processing an appropriate mixture of microorganisms in a predetermined sequence, by modifying these processes with specifically directed additions of useful substances and by appropriately modifying the times and temperatures of the various stages of these processes. this way, you discover a process which is suitable to produce dietary supplements that present a high degree of effectiveness that reach an adequate level so that the supplements
can be used for current therapeutic purposes. As indicated in the following part of this description, a dietary supplement that can be obtained by means of the processes according to the present invention, as a result of a broad spectrum and high concentrations of organic substances with beneficial effects they contain, not only proves useful. as a principal measure, as indicated above, for the prevention and therapy of conditions due to deficiencies of calcium, magnesium and potassium, but also exerts a secondary beneficial action in various different disorders that are generated by genetic factors in combination with functional imbalances of a chemical nature. We now describe a modality, which is neither mandatory nor exclusive, of the processes according to the present invention. This process essentially comprises the following steps: a) preparing a mixture at 18 ° C comprising one or more types of pasteurized milk of animal origin;
b) add to this mixture 1.5-4.5% by weight of the first granules consisting predominantly of bacteria; c) maintaining the mixture at 18-25 ° C for an initial period of time ranging from 6 to 12 hours and subsequently adding, after about half the process, 1-3% by weight of this pasteurized milk mixture; d) adding to the mixture 2.5-6.5% by weight of the second granules consisting predominantly of yeasts; e) keep the mixture obtained in this way at 18-25 ° C for a second period of time ranging from 6 to 12 hours and add to this calcium and / or magnesium and / or potassium in amounts of 0.2-1.2% by weight during the first half of this second period of time; f) filtering a residual matrix consisting of the granules that are introduced in the various stages of the process and the granules that are formed during the process itself; g) Dry the mixture after filtration to obtain a powder.
These first and second granules can be obtained by means of a conventional milk inoculation process, starting with commercially available Kefir granules. For the control and identification of bacteria for the normalization of the contents of these granules, reference can be made to the texts by M. Motaghi et al. (1997), Kandler-Weiss (1986) and Hardle (1986) for the first granules consisting mainly of bacteria, and the Barnet method (1990) for the second granules consisting mainly of yeasts. All the aforementioned publications are incorporated herein for reference. A profile indicative of the contents of these granules can be deduced from the attached Tables A and B.
Tables First granules Mainly (Table A) Lactobacillus bacteria 106-107 bre vi s Lactobacillus 106-107 casei
Lactobacillus 106-107 plantarum Lactobacillus 108-109 (optionally, kefir 'addition' of 20-30%)
Lactobacillus 107-108 (optionally, kefirano faciens "addition" of 20-30%
Acetobacter aceti 106-107 Leuconostoc 105-106 mesenteroids Streptococcus 104-105 lactis Others 105-106
Saccharomyces 103-104 lactis Sacch aromyc e 105-106 cerevisiae Saccharomyces 104-105 fragilis Candida kefir 104-10 £
Seconds granules Mainly Table B yeasts Lactobacillus 10 5-1 i06
brevis Lactobacillus 105-106 caseí Lactobacillus 105-106 plantarum Lactobacillus 106-107 kefir Lactobacillus 106-107 kefir ano faciens Acetobacter aceti 105-106
Leuconostoc 104-105 mesenteroids Streptococcus 10 -105 lactis Others 105-10É
Saccharomyces 105-106 lactis Saccharomyces 10d-107 cerevisiae Saccharomyces 105-106 fragilis Candida kefir 106-107
Other _ 105-106
The distinguishing characteristics of a dietary supplement obtained in this way, due to the particular mixture of bacilli and yeasts, which improve in an extraordinary way the Kefir previously mentioned (as well as other types of yogurt) are mainly the following: 1. Among the biological substances with high content of minerals such as calcium, magnesium and potassium, this dietary supplement surprisingly presents a profile that is much richer in other 'noble' substances, as an attribute to specific supplementation and of general value, such as amino acids of branched chains, polysaccharides and vitamins, these nutrients have been shown to significantly enhance the intestinal absorption of calcium and the metabolism of various minerals 2. The effect of microorganisms on lactose causes their conversion into lactic acid, which , in turn, is an 'intensifier' of calcium absorption, in addition to reducing s risks of lactose intolerance. This must be added to the fact that the microorganisms themselves produce an enzyme, galactosidase, which makes lactose digestible.
Finally, they are able to substantially reduce the absorption of cholesterol, and therefore protect the body against a well-known threat. 3. The presence of polysaccharides (slow-picking carbohydrates) also makes this product suitable for diabetics and for elderly patients in general. Branched chain amino acids are also important elements for elderly individuals by virtue of their basic function of growth and maintenance of muscle fibers (and therefore again provide additional support for the entire musculoskeletal system). Below is a detailed indicative profile of the constituents of the product in question. First, an example is given (Tables 1 to 5) of a formulation (nutrient complex) that is selected using a fermentation process according to the invention, which has the purpose of providing a supplementation of minerals such as calcium, magnesium and potassium, according to the criterion of the invention itself; this follows by the presentation (Table 6) of the composition of a dietary supplement, which is produced by means of 'specifically directed enrichment'
of the raw material and which is suitable for therapeutic and preventive applications in the field of osteoporosis: Composition of fermentation substances obtained by means of the processes according to the invention.
Table 1 General Analysis Constituents% ±% Protein 45 15 Humidity 5 10 Fat (1) Total lipids 4 2 Fiber 3 2 Carbohydrates 30 10 8 Minerals (ashes) 13 Calories per gram 2.8
Table 2
Minerals (mg per 100 g of product)
Constituents (±%)
Potassium 2240 20
Phosphorus 1320 15
Magnesium 180 30 Sodium 680 15 Calcium 1660 20 Zinc 2.3 20 Iron 4.5 10 Chromium 146 μg Selenium 13.3 μg Copper 0.3 20
Manganese Traces
Table 3 Vitamins (mg per 100 g of product) Constituents (+ 25%) Bi (thiamine) 6.6 B2 (riboflavin) 5.6 Niacin 54 B6 (pyridoxine HCl) 4 B12 50 μg Folic Acid 1.4
Biotin (H) 180 μg
Inositol 300 Hill 453.3
Para-aminobenzoic acid 2.4
Table 4 Amino acids (mg per 100 g of product)
Constituents (+ 20%) Arginine 3200 Glutamic Acid 13100 Histidine 2000 Isoleucine 4300 Leucine 7500 Lysine '6700 Methionine 1400 Phenylalanine 3500 Threonine 5200 Triptofan 1800 Tyrosine 3200 Valine 4800
56700
Table 5 Constituent Nucleic Acids (+ 30%)
Total 8-9%
Example of dietary supplement for osteoplasia.
Table 6 Content (for roughness 5% approximation) Value in g 100 g Sachet 2 tablets! (10 g) (12 g) Protein 45 4.5 5.40 I! Carbohydrates 30 3.0 3.60 1 Fat 1 0.1 0.12 Total lipids 4 0.4 0.48 i Fiber 3 0.3 0.36 Minerals 13. 1.3 1.56 Humidity 4 0.4 0.48 1 Calories 280 28.0 33.60
Dietary supplements that are produced by the process of the present invention have been tested, and extensively analyzed, and demonstrate that
they possess in an effective way the desired characteristics, which allow remarkable advantages over the traditional calcium supplements that are to be obtained. The main advantages that are particularly worth mentioning are as follows: • The presence, in the supplements obtained in this way, of substantial amounts of calcium and other minerals in greater quantities than in the commonly used dietary supplements. • A high degree of intestinal absorption and bioavailability of the minerals that are contained in the supplement for the bones and the body and, therefore, a greater efficiency and efficacy in comparison to the commonly used products. • A high degree of tolerance to the supplement, much higher than that of dairy products, as a result of solving the problem of lactose. • Lower amounts of cholesterol that is absorbed compared to the various dairy products that are recommended in diets for osteoporosis. • Optimal efficacy due to the presence in the supplement of a complete nutritional profile of biological origin, and not a simple 'mixture' of substances unrelated to each other.
additional "that operate along with the mineral profile, a variety of these confer current advantages to be achieved that are unattainable in the other commonly recommended dietary supplements and nutritional substances: - branched chain amino acids (beneficial to the entire musculoskeletal system) - polysaccharides ( advantageous for the elderly and for diabetics) - vitamins (which complete the nutritional profile) • The substance, which can be obtained by lyophilization as a dry powder with a pleasant taste, is presented in very practical formulations, such as chewable tablets and sachets with the contents to be dissolved in liquids, with, among other things, also allow high doses of the product to be administered by a single daily administration.This is also because the formulation that is obtained makes any prolonged or delayed release form of the substance is superflu • Finally, the formulation derived from the fermentation process' Kéfir type "has proven to be ideal, and consequently differs completely from the others
calcium and mineral supplements, for constituting a multifunctional 'substrate' as the basis for producing dietary supplements in various areas of application for preventive and / or supportive treatments in various conditions of deficiencies (poor nutritional diets, metabolic dysfunctions), immunodeficient states , degenerative diseases (of the bones, skin dystrophy), senility, physiological transition periods (menopause) In all these applications, an important role is probably played in the multifunctional 'probiotic' activity of the biological matrix of lactobacilli and yeasts and their immunostimulant and bioprotective activity as studied by various researchers.
It is noted that in relation to this date, the best known method for the applicant to carry out the aforementioned invention, is the conventional one for the manufacture of the objects or products to which it refers.
Claims (6)
1. A process for the preparation of dietary supplements by natural fermentation, characterized in that it comprises the following steps: a) preparing a mixture at 18 ° C comprising one or more types of pasteurized milk of animal origin; b) add to this mixture 1.5-4.5% by weight of the first granules consisting predominantly of bacteria; c) maintaining the mixture at 18-25 ° C for an initial period of time ranging from 6 to 12 hours and subsequently adding, after about half the process, 1-3% by weight of this pasteurized milk mixture; d) adding to the mixture 2.5-6.5% by weight of the second granules consisting predominantly of yeasts; e) keep the mixture obtained in this way at 18-25 ° C for a second period of time ranging from 6 to 12 hours and add to it, calcium and / or magnesium and / or potassium in amounts of 1-2% by weight during the first half of this second period of time; f) filtering a residual matrix consisting of the granules that are introduced in the various stages of the process and the granules that are formed during the process itself; g) Dry the mixture after filtration to obtain a powder.
2. The process according to claim 1, characterized in that: h) the mixture comprises 50-100% by weight of cow's milk and 0-50% by weight of • at least one milk selected from a group consisting of sheep's milk, goat's milk, and mare's milk; i) the first granules consisting predominantly of bacteria are of the type used for the production of Kefir and contain: Lactobacillus brevis 106-107 Lactobacill us casei 106-107 106-107 Lactobacill us plantarum Lactobacill us kefir 10 -10- (optionally, "addition" of 20-30%) Lactobacill us 107-108 (optionally, "addition" kefir year Faciens 20-30% Acetobacter aceti 106- 107 Leuconostoc 105-106 mesenteroids Streptococcus lactis 104-105 Others 105-106 Saccharomyces lactis 103-104 Saccharomyces 105-106 cerevisiae Saccharomyces fragili s 104-105 Candida kefir 104-105 1) After the introduction of the first granules, Lactobacill us kefir and Lactobacillus kefiranofaciens bacteria can be added in amounts of 20-30% by weight of bacteria of the same species that are already present in the first granules. m) the second granules consist predominantly of yeasts containing: Lactobacill us brevis 105-106 Lactobacill us casei 105-106 105-106 Lactobacill us plantarum Lactobacill us kefir 106-107 106- 107 Lactobacill us Acetobacter aceti kefirano faci ens 105-106 Leuconostoc mesenteroides Streptococcus lactis 104-105 104-105 105- Other 106 Saccharomyces lactis 10 5- -1t n06 Saccharomyces 106-107 cerevi siae Saccharomyces fragili s 105-10d Candi da kefir 106-107 Others 105-106
3. The process according to claim 2, characterized in that the initial mixture comprises 80% by weight of cow's milk and 20% by weight of sheep's milk.
4. The process according to any of the preceding claims, characterized in that it also comprises the following steps: add flavoring agents, optionally add an adherent agent to confer the powder a greater cohesion and compact the powder that is added in this way to obtain chewable tablets.
5. A dietary supplement obtained by the process described according to any of the preceding claims.
6. Use of a dietary supplement obtained via the process according to the preceding claims for preparing a composition for the prevention and treatment of osteoporosis and other diseases due to calcium deficiency, magnesium and potassium in the body. SUMMARY OF THE INVENTION A process for manufacturing dietary supplements (food integrators) by means of natural fermentation is described which includes the following steps: a) preparing a 'mixture' at 18 ° C containing one or more types of pasteurized milk of origin animal; b) introduction in this 'basic material' of 1.5-4.5% by weight of 'granules' of polysaccharides that are formed mainly from 'friendly bacteria'; c) maintenance of the previous substance at 18-25 ° C temperature for a first period of time of 6-12 hours and then adding an amount of 1-3% by weight of a second combination of 'granules' of polysaccharides, which they are formed mainly of yeasts, d) maintenance of the substance at 18-25 ° C during a second period of time of 6-12 hours, again when adding 2.5-6.5% by weight of 'granules' that are formed mainly by yeast, and then add some minerals (calcium, magnesium, etc.) in a proportion of 0.2-1.2% by weight; e) separation, by filtration, of the different components of the substances, among which there is a 'residual matrix' composed of polysaccharide granules containing bacteria and yeasts, f) drying the substance, after the filtration, to obtain a fine powder; g) preparation of the various dietary supplements, which are presented in tablets or "sachets" or other formulations, useful for the treatment of osteoporosis and other degenerative conditions.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH683/99 | 1999-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00012300A true MXPA00012300A (en) | 2001-12-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU775104B2 (en) | Dietary supplement derived from fermented milks for the prevention of osteoporosis | |
CA2262652C (en) | Anti-stress drugs and functional foods having anti-stress effects | |
CN103653170B (en) | Stachyose probiotics solid beverage | |
RU2549709C1 (en) | Probiotic sour cream production method | |
JPH03505520A (en) | Nutrient composition and its manufacturing method | |
CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
Yadav et al. | Concise review: importance of probiotics yogurt for human health improvement | |
CN1065411C (en) | Healthful nutrition milk powder and production method | |
US6368641B1 (en) | Lactic acid bacteria and food products | |
Goswami et al. | Implication of functional ingredients of goat milk to develop functional foods | |
CN101112210B (en) | Onion biological fermentation emulsion and the producing method thereof | |
CN102077872B (en) | Fruit vinegar-containing milk beverage and preparation method thereof | |
Kryuchkova et al. | Vegetable ingredients in functional fermented milk products | |
JP2005312424A (en) | Method for producing fermented product using kefir grain, and fermented product obtained by the same | |
CN102742654A (en) | Beautification probiotic ewe milk tablet and preparation method thereof | |
MXPA00012300A (en) | Dietary supplement derived from fermented milks for the prevention of osteoporosis | |
RU2276848C1 (en) | Composition for preparing of cultured milk product for gerodietary feeding | |
RU2789462C1 (en) | Ferrous milk product for gerodietic nutrition | |
Novhorodska | Sour milk drink with prebiotic properties | |
RU2196432C1 (en) | Composition for preparing cultured milk product for herodietary alimentation | |
Petrova | Increasing the bioavailability of nutrients in fermented dairy products | |
GURR | Health benefits of cultured and culture‐containing milks | |
CZ20004619A3 (en) | Dietary supplement derived from fermented milks for the prevention of osteoporosis | |
JPH1146720A (en) | Nutritive composition for promoting absorption of calcium | |
CN111194777A (en) | Quinoa yoghourt and preparation method thereof |